Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE: Ramucirumab + FOLFIRI in 2nd-line mCRC
NCT01183780Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Primary completion
- Jul 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of ramucirumab in metastatic colorectal cancer (mCRC), sponsored by Eli Lilly and Company. Started Dec 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01183780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183780.